Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...
Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback